Novartis vaccine Bexsero combats meningitis

Tools

Novartis ($NVS) is reporting its vaccine Bexsero stimulated an immune response against three strains of the meningococcus B bacterium. An approval would open the door to jabs that would combat the full slate of serogroups that are the primary cause of meningococcal disease around the world. The CDC's Amanda Cohn and Nancy Messonnier called it a "major step forward." Story

Filed Under